What is the Parkinson Study Group (PSG)?

The Parkinson Study Group (PSG) is a non-profit group of physicians and other health care providers from medical centers in the United States, Canada and Puerto Rico experienced in the care of Parkinson patients and dedicated to clinical research of Parkinson disease. The PSG was formed in 1986, prompted by the recognition that clinical research in Parkinson disease (PD) required the participation of large numbers of research patients (subjects) under the cooperative care of skilled and experienced research physicians.

The PSG aims to advance knowledge about the cause(s), disease progression and treatment of PD and related disorders. The PSG is committed to:

  • open communication within the scientific community;
  • ensuring research is peer reviewed by other health care providers prior to publication and that all research results are available to the public;
  • revealing potential conflicts of interest of the group and each PSG member and;
  • democratic governance of its organizations and activities.

The PSG Advantage: Four Reasons to Partner with PSG

Our Network

We are the longest standing, largest and most experienced network of committed and credentialed PD Centers for over 25 years! Our network comprises 132 credentialed PD Centers throughout North America. We take great pride in our strict credentialing process whereby only Clinical Trial Centers with substantial experience and expertise in the care of PD patients can be members of our network.

Our Comprehensive Service and Flexibility

Sponsors can choose to partner with the PSG for the entire clinical trial life cycle from protocol creation to FDA application; or “cherry-pick” from the following services coupled to PSG trials:

  •      Protocol creation/modification
  •      Event planning for the Investigator’s Meeting
  •      Project Management
  •      Clinical Monitoring
  •      Data Management

Our Track Record

We have completed over 40 Parkinson clinical trials enrolling from 8 to 800+ subjects, totaling more than 7,000 Parkinson patients. More importantly, our clinical trials have been instrumental in FDA approval of 4 Parkinson drugs:

  •      Rasagiline
  •      Rotigotine
  •      Entacapone
  •      Pramipexole

Our Reputation

Above all else, the Parkinson Study Group is most known for the scientific rigor in the way it conducts its clinical trials and for the high quality of its publications, providing the greatest impact and longevity of drugs investigated.  Our standing among PD stakeholders is reflected in our 200+ scientific publications and our contributions to successful FDA applications.

PSG Executive Committee

The PSG is governed by a Constitution and Bylaws and an elected Executive Committee that is primarily responsible for the direction and oversight of its research projects and activities.

Key Documents

Click below to view/download PDF documents:

PSG Bylaws
PSG Policies & Procedures
Conflict of Interest Guidelines

Executive Committee Overview

The PSG Executive Committee oversees all the PSG study steering committees, the Scientific Review Committee, the Mentoring Committee, the Nominating Committee, the Credentials Committee, the Publications Committee, the Standards Committee, the Study Budget Committee, and the Symposia Committee (Click here to view/download the PSG Standing Committee Members list). The Executive Committee is also responsible for overseeing the PSG working groups (Atypical Parkinsonian Disorders, Cognitive/Psychiatric (Behavior), Biomarkers, Genetics and Environmental Risk, Health/Care Outcomes and Disparities, Other Non-Motor Features of PD, Functional Neurosurgical and Motor Features of PD) that are responsible for developing new PSG projects. PSG members interested in joining a working group may contact the Chair of that group.

Executive Committee Members

PSG Executive Committee Members:
Cindy Casaceli (2015-2018)
Kelvin Chou (2017-2020)
Eric Macklin (2015-2018)
Peter LeWitt (2015-2018)
Brad Racette (2018-2021)
Marie Saint-Hilaire (2018-2021)
David K. Simon (2017-2020)
Karen Williams (2018-2021)

Ex-officio members:
Karen Rabinowitz, JD, Legal Counsel
Roseanna Battista, BS, Administrative Manager
Donna Moszkowicz, CMP, Development and Event Manager
Cindy Wan, BS, PSG Financial Administrator (2013-present)

PSG Chair and Co-chair:

Michael Schwarzschild, MD, PhD, Chair (2018-2024)

Hubert Fernandez, MD, Co-Chair (2018-2024)

Click here to download the Executive Committee position statement.

Click here to download the Standing Committee list.

Scientific Review Committee

The Scientific Review Committee will review all PSG research proposals including retrospective data mining projects and prospective studies, whether observational or interventional. A primary and secondary reviewer will be assigned and the Committee will review and score each proposal. The Committee will also facilitate contacts with the Mentoring Committee as appropriate. Requests for use of PSG repositories (DNA, CSF, blood, urine, video) will also be reviewed by the Scientific Review Committee. The Scientific Review Committee will consist of a chair and approximately ten to fifteen members to serve terms of three years and will rotate off one third of its members every year. 

Outline for Review of Proposals Submitted to the PSG

Prior to submitting any proposal to the PSG, we encourage all investigators to make use of the PSG Working Groups and get assistance, if needed, from the PSG Mentoring Committee.

Note: For projects requiring access to the DATATOP biospecimen repository, a separate proposal review and funding mechanism is now managed through NINDS at https://pdbp.ninds.nih.gov/pd-brac .

  1. Proposal is submitted to PSG and reviewed by PSG Chair and Co-chair
  2. Proposal is assigned a primary and secondary reviewer from the Scientific Review Committee (SRC)
  3. Primary and secondary reviewers submit their review within 30 days of receipt
  4. Proposal and reviews are distributed to the SRC
  5. SRC rates the proposal using the NIH 9-point scoring system. Individual reviewer scores will be averaged and the result multiplied by 10 to determine the final impact/priority score (range of 10 to 90)
  6. Proposal is approved, approved with criticisms, or not approved
  7. Proposals with criticisms are referred to the PSG Executive Committee
  8. Reimbursement of $200 per review

Submissions due 30 days before SRC meeting and responses back to proposing investigator within 30 days of SRC meeting. SRC meets 3x/year, every 4 months.

Submissions due: 4/1/19
SRC Meeting: May 2019
Response to PI's: 6/14/19

Submissions due: 8/1/19
SRC Meeting: September 2019
Response to PI's: 10/1/19

Submissions due: 12/2/19
SRC Meeting: January 2020
Response to PI's: 2/3/20

Click here to download the RFP.

The Procedures for Submission and Review of Proposals is also available in the New Study Proposal Toolkit.

NeuroNEXT opportunities

NeuroNEXT provides an established infrastructure including a data coordinating center (University of Iowa), Clinical Coordinating Center (Massachusetts General Hospital) and approximately 28 study sites. Funded NeuroNEXT studies will use this infrastructure which includes central IRB and pre-established contractual agreements with all sites. All but 3 NeuroNEXT sites are also Parkinson Study Group sites.

Academics, foundations and industry are eligible to submit proposals to NeuroNEXT. Initially, a brief Study Concept Synopsis is evaluated for mission relevance and feasibility by the NeuroNEXT Executive Committee (NEC). Proposals which are found to be mission relevant, feasible and of sufficient priority are referred to protocol working groups for development of grant applications. The resulting grant application would be submitted for NINDS peer review.

Find the NeuroNEXT Clinical Study Concept Synopsis here: http://www.neuronext.org/

PSG DATATOP biospecimens research: Projects requiring access to the DATATOP biospecimen repository a separate proposal review and funding mechanism has been developed in collaboration with The Michael J. Fox Foundation (MJFF) and the NINDS Parkinson’s Disease Biomarkers Program (PDBP) and supports the identification and validation of novel biomarkers through use of DATATOP biospecimens.

The Michael J. Fox Foundation is now accepting pre-proposals to our Use of Parkinson’s Disease Biosamples Request for Applications (RFA). Awards are up to $300,000 for a one- to two-year grant. The deadline for pre-proposals is September 24, 2019, at 5 p.m. ET. Awards include funding and accompanying biosamples for research programs focusing on Parkinson’s target and assay development. The Foundation is especially interested in studies focused on:

Assay development and validation for novel biomarkers

Biomarker replication and validation of promising measures that associate with Parkinson’s or progression

Target discovery and validation

Apply Now.

Utilizing DATATOP Biospecimens

PSG DATATOP biospecimens research: Projects requiring access to the DATATOP biospecimen repository a separate proposal review and funding mechanism has been developed in collaboration with The Michael J. Fox Foundation (MJFF) and the NINDS Parkinson’s Disease Biomarkers Program (PDBP) and supports the identification and validation of novel biomarkers through use of DATATOP biospecimens.

MJFF Use of PD Biosamples RFA

The Michael J. Fox Foundation is now accepting pre-proposals to our Use of Parkinson’s Disease Biosamples Request for Applications (RFA).

Awards are up to $300,000 for a one- to two-year grant. The deadline for pre-proposals is September 24, 2019, at 5 p.m. ET. Awards include funding and accompanying biosamples for research programs focusing on Parkinson’s target and assay development. The Foundation is especially interested in studies focused on:

  • Assay development and validation for novel biomarkers
  • Biomarker replication and validation of promising measures that associate with Parkinson’s or progression
  • Target discovery and validation

Apply Now.

Who Serves on the PSG SRC? 

Download a PDF of the member list here. 

Chair and Co-chair

Peter A. LeWitt, MD, Chair (2016-2020)
Professor of Neurology, Wayne State University School of Medicine
Director, Parkinson's Disease & Movement Disorders Program
Henry Ford West Bloomfield Hospital
6777 West Maple Road
West Bloomfield, MI 48034
(248) 325-2452     (248) 325-2452     Fax: (248) 325-3115
palewitt@ameritech.net     alternate email: plewitt1@hfhs.org
Contact, if necessary: Julia Wall - jwall1@hfhs.org

Joel Perlmutter, MD, Co-Chair (2016-2020)
Washington University School of Medicine
Department of Neurology
660 South Euclid Box 8111
St Louis, MO 63110
(314) 362-6026     Fax: (314) 362-0168
Assistant: Susan Donovan donovan@npg.wustl.edu


Sharon Xie, PhD (2016-2019)
Department of Biostatistics and Epidemiology
University of Pennsylvania
Perelman School of Medicine
607 Blockley Hall
423 Guardian Drive
Philadelphia, PA 19104-6021
(215) 573-3867     Fax: (215) 573-4865
Download Dr. Xie's bio here.

Christopher A. Beck, PhD (2019-2022)
Associate Professor
Department of Biostatistics & Computational Biology
University of Rochester Medical Center
601 Elmwood Avenue, Box 630
Rochester, NY 14642
(585) 275-6781     Fax: (585) 273-1031
Download Dr. Beck's bio here.

General Clinical

James Boyd, MD (2016-2019)
University of Vermont
1 S. Prospect Street, Arnold 2, Neurology
Burlington, VT 05401
(802) 847-4589     Fax: (802) 847-2461

Irene Richard, MD (2016-2019)
University of Rochester
919 Westfall Rd.
Building C, Suite 220
Rochester, NY 14618
(585) 341-7500     Fax: (585) 341-7510
Download Dr. Richard's bio here.

Marie Saint-Hilaire, MD (2016-2019)
Boston University Medical Center
Department of Neurology
72 East Concord Street C3
Boston MA 02118
(617) 638-8456     Fax: (617) 638-5334

Basic Science

M. Maral Mouradian, MD (2018-2021)
William Dow Lovett Professor of Neurology
Director, Center for Neurodegenerative and Neuroimmunologic Diseases
Director of Research, Department of Neurology
Chief, Division of Translational Neuroscience
Rutgers - Robert Wood Johnson Medical School
683 Hoes Lane West, Room 180
Piscataway, NJ 08854
(723) 235-4772     Fax: (732) 235-4773
Staff Assistant: Shiela Reaves reavessh@rwjms.rutgers.edu
Download Dr. Mouradian's bio here.

Joseph Savitt, PhD (2018-2021)
University of Maryland School of Medicine
Associate Professor of Neurology
110 S. Paca Street, 3rd Floor
Baltimore, Maryland 21201
(410) 328-7809     Fax: (410) 328-0167
Download Dr. Savitt's bio here.

Genetics/Genetic Epi

Rachel Saunders-Pullman, MD, MPH (2016-2019)
Associate Professor of Neurology
Icahn Mount School of Medicine at Mount Sinai
Department of Neurology
Mount Sinai Beth Israel Medical Center
10 Union Square East, Suite 5J
New York, NY 10003
(212) 844-8719     Fax: (212) 844-8710

Marta San Luciano Palenzuela, MD (2018-2021)
University of California, San Francisco
1635 Divisadero Street, Suite 520
San Francisco, CA 94115
(415) 353-2311     Fax: (415) 353-9060
Download Dr. San Luciano's bio here.


Gregory Pontone, MD, MHS (2018-2021)
Director, Parkinson’s Neuropsychiatry Clinical Programs
Johns Hopkins University School of Medicine
Morris K. Udall Parkinson's Disease Research Center
Associate Professor, Departments of Psychiatry and Neurology
(410) 502-0477
Download Dr. Pontone's bio here.

Neurosurgery/Surgical Clinical Trials

Philip Starr, MD, PhD (2018-2021)
University of California, San Francisco
1635 Divisadero Street, Suite 520
San Francisco, CA
(415) 353-2311     Fax: (415) 353-9060
Download Dr. Starr's bio here.

Mentoring Committee

What is the PSG Mentoring Committee (MC)?

The PSG Mentoring Committee (MC) has three main roles.

  1. To solicit, review, and select candidates to receive the Parkinson’s Disease Foundation supported mentored clinical research award. This is a major award in support of a project that is a practical training ground for individuals to acquire new skills and expertise in clinical research.

  2. To serve as a resource for individuals who need assistance in formulating and developing protocols to the point where they are ready for review by the Scientific Review Committee.

  3. To develop and organize innovative programs to promote interest in Parkinson’s disease research, facilitate the development of mentorship relationships, and increase awareness of resources within the PSG that can provide opportunities for initiating research efforts.

The Mentoring Committee oversees the PSG Advisor Program. Implemented in 2009, the PSG Advisor Program helps new investigators find a local mentor or specific research funding sources for their research.

Mentoring Committee Members

Download a Word doc of the member list here.

Brad A. Racette, MD, Chair (2018-2021)
Washington University School of Medicine
Department of Neurology
660 South Euclid Avenue Campus Box 8111
St Louis, MO 63110
(314) 362-8548     Fax: (314) 747-8289
Assistant: Tracey Erdman - erdmant@neuro.wustl.edu

James Leverenz, MD, Co-Chair (2018-2021)
Director, Cleveland Lou Ruvo Center for Brain Health
Dr. Joseph Hahn Endowed Chair of Neurological Sciences
Cleveland Clinic
9500 Euclid Avenue, U10
Cleveland, OH 44195
(216) 636-4044
Assistant: Shelley Sekerak - SEKERAS2@ccf.org

Roy Alcalay, MD
Columbia University

John L. Goudreau, DO, PhD (2018-2021)
Director, Translational Neurobiology Research Unit Director, Movement Disorders Clinic
Associate Professor Department of Neurology Department of Pharmacology & Toxicology
B407 Clinical Center
Michigan State University
East Lansing, MI 48824
(517) 432-9277     Fax: (517)-432-9414
Assistant: Krista Leiter: Krista.Leiter@hc.msu.edu

Emily (Dunn) Hill, M.D.
Baylor College of Medicine
Parkinson’s Disease Center and Movement Disorders Program
7200 Cambridge, 9A
Houston, TX 77030
Download Dr. Hill's bio here.

Baijayanta Maiti, PhD (2016-2019)
Fellow, Movement Disorders
Washington University in St. Louis
660 S Euclid Avenue
St. Louis, MO 63110
(314)362-6902     Fax: (314)362-0168

Michael McDermott, PhD
University of Rochester
Department of Biostatistics
601 Elmwood Avenue Box 630
Rochester, NY 14642
(585)275-6685     (585)275-6685     Fax: (585)273-1031
Download Dr. McDermott's bio here.

Matthew N. Petrucci, PhD (2017-2020)
Postdoctoral Research Fellow, Department of Neurology
Movement Disorders Laboratory, University of Minnesota
717 Delaware St. SE, Room 516
Minneapolis, MN, 55414
Download Dr. Petrucci's bio here.

Allison Willis, MD
University of Pennsylvania

Cynthia Comella, MD (Advisor Program)
Rush University Medical Center
Department of Neurological Sciences
1725 West Harrison, Suite 755
Chicago, IL 60612
(312)563-2900     (312)563-2900     Fax: (312)563-2684
Assistant: Tracy Waliczek
Download Dr. Comella's bio here.

PSG Visiting Mentorship Program

Program Overview

The PSG Visiting Mentorship Program is funded by a grant from Sunovion Pharmaceuticals. The goal of this program is to promote the continued development of newly trained movement disorders clinician-researchers into world-class investigators. This initiative focuses on the mentorship of young investigators committed to clinical research in the Parkinson arena by seasoned, established clinical investigators. While there are several courses and conference that a young investigator can participate in, there is no substitute for a personal mentor-mentee relationship, where the mentor can review the mentee’s proposed initiative(s), and meet with the mentee’s team, local set up, and provide in-person sage advice.

Available funds: PSG will award up to four awards totaling $7,450, including $5,000 for mentor honorarium and $2,450 for travel, meals, and incidentals related to mentoring.

The Project:

  • Project period is 1 year beginning July 1, 2019 and ending June 30, 2020.

  • Needs to be an investigation into an aspect of PD.

  • The investigators/research can be basic, translational, or clinical.

  • The short and long-term goals of the project should be clearly stated.

  • The reason(s) why a visiting mentorship is critical to the project should be described.

An electronic copy of the proposal in pdf-format must be received by the PSG on or before Friday, June 7, 2019. Applications should be sent by to email to Roseanna Battista.

To download a copy of the RFP for this program, click here.

PSG Advisor Program

Program Overview

The Parkinson Study Group (PSG) Mentoring Committee has an Advisor Program for new investigators who are initiating a research career or continuing work in an existing research area. This program is managed by the PSG Mentoring Committee chaired by Drs. Jon Stoessl and Roger Albin with members James Boyd, Jessica Calleo, Wendy Galpern, Jennifer Goldman, Michael McDermott, John Nutt, Kristen Pickett, Fredy Revilla, Joshua Shulman and Cynthia Comella.

A bank of advisors who are leading experts in Parkinson disease research are available to help investigators find a local mentor in their area (both research and geographic) or to provide general advice for pursuing specific research funding sources (foundations, etc.) are available. The advisors are not mentors per se, but rather facilitate finding a mentor or help the investigator begin a research career in a certain area.

To participate in this program, email Roseanna Battista for an application form.

After receiving your application and CV, the following steps will be taken:

  • We will select an appropriate advisor from our databank of voulunteers;

  • We will forward the name/email of the selected advisor to you within 7 business days;

  • You will then be able to contact the advisor via email to introduce yourself and set up an appropriate means of contact.

Both the advisor and advisee will keep confidential any information received or obtained as a result of participating in the program that is identified as confidential, or would be reasonably expected to be confidential, unless they agree otherwise.

We will solicit feedback from those using this program periodically. Questions regarding this program can be directed to Roseanna Battista.


Tara McIsaac, PT, PhD from Columbia University applied to the PSG Advisor Program because she needed help with career planning and development. Her specific area of interest is the affect of PD on multi-segment motor control during dual task activities, such as driving. She was matched with Daniel Corcos, PhD from the University of Illinois at Chicago because of his expertise in motor deficits in PD.

“The PSG mentoring program provided a valuable opportunity for me as a new investigator seeking grant-writing guidance to be paired with an experienced researcher within my area of study. The mentor selected for me was a great match! Thank you.”
– Tara McIsaac, Advisee

“I have enjoyed working with Tara because it has helped me to clarify my own thinking in terms of what is important for young investigators to focus on. I have also learned and benefited from talking to Tara and reading some of her work in terms of understanding more about what patients with Parkinson's disease find difficult when trying to perform two tasks at the same time. The benefit of the PSG program is that is pairs scientists with different knowledge bases at different stages of their careers and it allows them to learn from each other.”
–Daniel Corcos, Advisor

PSG International Collaborators

Parkinson Research Alliance of India (PRAI)

Karl Kieburtz, PI

A two-day in-person meeting was held last January, 2012, in New Delhi, India, to introduce the groups in person and to begin training efforts, and another in-person meeting was held on February 8-9, 2013, in New Delhi.

A couple small projects developed by the group at the January meeting have already been completed. Also, many of the aims of the grant have been accomplished, including training of the Indian investigators of PRAI on the MDS-UPDRS and training on the Unified Dyskinesia Rating Scale has begun. Also the PRAI investigators have completed training on the eClinical electronic data capture system. Additionally all of the PRAI investigators who were in attendance at last year’s in-person meeting have now become members of The Movement Disorders Society (MDS), which facilitated their training on the MDS-UPDRS, and will help facilitate training on the UDysRS as well. An additional project idea developed by the group at last year’s in-person meeting was the translation of the MDS-UPDRS into Indian dialects, such as Hindi, Marathi and Bengali. The India PI Dr. Behari and her colleagues have already translated the MDS-UPDRS into Hindi. One of the other projects developed was to assess the agreement between investigators when rating individual patients, as an assessment of the quality of the examinations, which has been operationalized as a comparison between senior and junior raters of the MDS-UPDRS. This project has already begun in the US and the protocol is under review by the India sites to submit to their local IRBs. This small inter-rater reliability project is especially useful for the goals of the CPPD, as it utilizes several aims of the project, including recent training on PD scales, use of the eClinical system, and overall collaboration between US and India.

Despite some initial difficulties with the India government's release of funding to the India PI, this project is moving along. This grant is a two-year R21 grant from NIH.

International Colleagues

Piu Chan MD, PhD

Director, Beijing Institute of Geriatrics and Department of Neurology Xuanwu Hospital of Capital University of Medical Sciences

Dr. Chan graduated from Human Medical College in Changsha, China with a MD and became a neurologist after the fellowship training. He later acquired his PhD on neurosciences from Sun Yan-Set University of Medical Sciences in Guangzhou, China and followed by postdoctoral training at the Parkinson's Institute in Sunnyvale USA. He is currently the Professor of Neurology and Neurobiology of the Capital University of Medical Sciences, and the Director of the Beijing Institute of Geriatrics at the Xuanwu Hospital in Beijing, China and Adjunct Scientist at the Parkinson's Institute, Sunnyvale, California, USA where he has worked for more than ten years before returned to China in 2000. In addition, Dr. Chan is the director of the Chinese Parkinson Study Group and the deputy director of the Movement Disorder Section of the Chinese Neurological Association of the Chinese Medical Association. He is also the deputy director of the Chinese National Human Genome Center Beijing. Dr. Chan has published more than 250 peer reviewed papers in English and Chinese.

He was the Principal Investigator of a project awarded by EPA to study the susceptibility genes in a multi-center study in China. Since his return to China, he has continued to study the distribution of and risk factors for Parkinson's and Alzheimer's diseases in a few unique cohorts in China. He has initiated projects investigating the role for Traditional Chinese Medicine in prevention of neurodegenerative diseases. He has been awarded several times as First Prize by the Chinese Medical Association and Ministry of Education of China for his work on genetics of Parkinson's disease.

Jennifer Zheng

Beijing Institute of Geriatrics and Department of Neurology

Jennifer Zheng is a senior statistician in Beijing Institute of Geriatrics, Xuanwu Hospital, Capital Medical University. She got her master degree in Biostatistics from University of South Florida in 2002 and has been working on clinical research in both academic and industry settings. Before joined Xuanwu Hospital, she had been worked for Florida Mental Health Institute, Beth Israel Deaconess Medical Center and Sanofi-Aventis as a SAS programmer and biostatistician for more eight years. She has published and finished statistical analysis for more than ten international clinical trials and several large-scale epidemiology studies.

Wolfgang H. Oertel, MD

Professor for Neurology and Director of the Department of Neurology, The Philipps University, Marburg, Germany

Dr. Oertel obtained his MD at the University of Berlin, Germany. He completed his postgraduate neuroscience training at the Laboratory of Clinical Sciences at the National Institute of Mental Health, NIH, Bethesda, Maryland, USA. He is full professor for neurology and director of the Department of Neurology at the Philipps University Marburg, Germany, a Centre of Excellence of the US National Parkinson Foundation. Wolfgang H. Oertel is currently speaker of the Competence Network on Parkinson's Disease (an outstanding infrastructure for medical research in Germany) and chairman of the German Parkinson Study Group. Since 2011 he is president of the German Society of Neurology and liaison professor of the German National Academic Foundation at the Philipps-University of Marburg. He received the Parkinson-Frosst Award (1986) and the Dingebaur-Price for Parkinson research (2004) from the German Society of Neurology and the "carrier award for basal ganglia disorders" from the German Research Foundation (1987-1990).

Dr. Oertel's research interests focus on the diagnosis and treatment of neurodegenerative disorders (particularly Parkinson's disease and atypical parkinsonian syndromes) as well as sleep disorders (especially REM-sleep-behaviour-disorder and restless-legs-syndrome). He has profound expertise in the design and conduct of diagnostic and therapeutical trials in these fields and has been principal investigator or co-principal investigator in numerous clinical trials.

Kapil Dev Sethi, MD, FRCP

Representing PRAI (Parkinson Research Alliance of India)

Kapil Dev Sethi, MD, FRCP is Professor of Neurology at the Medical College of Georgia, Augusta, Georgia. He also serves as the Director of the Movement Disorders Center at MCG. Dr. Sethi is board certified in Neurology and Internal medicine.

Dr. Sethi earned his medical degree at the Christian Medical College, Ludhiana, India. After completing his residency in Internal Medicine and Neurology at the Post Graduate Institute of Medical Education and Research, Chandigarh, India, he finished a research fellowship Charing Cross Group of Hospitals and Medical School, London, UK. He was a Registrar in Neurology at the Welsh National School of Medicine at Morriston Hospital, and served a Neurology residency at the Medical College of Georgia.

An author of numerous reviews, abstracts, book chapters, and journal articles, Dr. Sethi’s work has been published in peer-reviewed publications, including Neurology, Movement Disorders and Annals of Neurology. He serves as an Associate Editor for Movement Disorders and has served as a section editor for Current Neurology and Neurosciences Reviews and Medscape Neurology.

Dr. Sethi is a Fellow of the American Academy of Neurology and the Royal College of Physicians (London). He is the Vice President of the Tremor Research Group. He is a member of the PSG, American Neurological Association, the Movement Disorder Society, and the American Association of Physicians from India. He has served on the International Executive committee for the Movement Disorders Society and on the board of Directors of the AAN and has served as a Treasurer of the AANF. He also serves as the Chair of the Development Committee of the MDS and is the MDS appointee on the WHO advisory group for the revision of ICD-10.

With research interests in Parkinson’s disease, restless legs syndrome, and cervical dystonia, Dr. Sethi has participated as principal investigator in numerous clinical trials. He is a frequent invited lecturer and has held visiting professorships at Duke University, Emory University and MGH Boston, among others.

Filip Bergquist, MD, PhD

Swedish Parkinson Research Network, SWEPAR-net

Dr. Bergquist earned his medical degree in 1997at the University of Gothenburg, Sweden and went on to earn a PhD in pharmacology in 2002 at the University of Gothenburg. He did a postdoctoral fellowship at the University of Edinburgh from 2004-2008. Worked with Profs Dutia, Ludwig and Leng studying brain stem synaptic plasticity and mechanisms of neuropeptide release and function.

Currently, Dr. Bergquist is the Neurology registrar at Sahlgrenska University Hospital in Gothenburg and holds a Junior Research Position on a personal grant from the Swedish Research Council. He is a Board member of the recently formed Swedish Parkinson Research Network, SWEPAR-net. SWEPAR-net is a subordinate to the Swedish Movement Disorder Society and aims to stimulate preclinical, clinical and translational PD related research in Sweden.

Dr. Bergquist has a translational research profile encompassing Parkinson disease animal models, behavior and in vivo neurochemistry, in vivo physiology and clinical patophysiology. His PhD thesis described the downstream permissive role of nigral somatodendritic dopamine release for motor functions, and he has since then also worked with models of brain stem synaptic plasticity and its role in posture and balance. Recent projects concern deficits in spatial memory strategies in PD patients and the role of sensory noise for motor-, and cognitive function in the dopamine depleted brain, and in Parkinson’s disease in particular.

Selected publications:

Andersson D., Nissbrandt H. and Bergquist F. (2006). ''Partial depletion of dopamine in substantia nigra impairs motor performance without altering striatal dopamine neurotransmission'' Eur J Neurosci 24:617-624.

Brederlau A., Correia A.S., Anisimov S.V., Elmi M., Paul G., Roybon L., Morizane A., Bergquist F., Riebe I., Nannmark U., Carta M., Hanse E., Takahashi J., Sasai Y., Funa K., Brundin P., Eriksson P.S .& Li J.Y. (2006). Transplantation of human embryonic stem cell-derived cells to a rat model of Parkinson's disease: effect of in vitro differentiation on graft survival and teratoma formation. Stem Cells 24, 1433-1440.

Bergquist, F., Ruthven, A., Ludwig, M. and Dutia, M.B (2006). “Histaminergic and glycinergic modulation of GABA release in the vestibular nuclei of normal and labyrinthectomised rats”, J Physiol, 577:857-868.

Bergquist, F., Ludwig, M. and Dutia, M.B (2008). “Role of the commissural inhibitory system in vestibular compensation in the rat”, J Physiol, 586:4441-4452.

Andersson, D.R., Björnsson, E., Bergquist F. and Nissbrandt H. (2009) “Motor activity-induced dopamine release in the substantia nigra is regulated by muscarinic receptors”, Exp Neurology, 221:251-259.

Pålsson E, Söderlund G, Klamer D, Bergquist F. (2010) Noise benefit in prepulse inhibition of the acoustic startle reflex. Psychopharmacology (Berl) pre-print online publication. DOI: 10.1007/s00213-010-2074-6.